IGF1 and acromegaly: PATHFNDR-1 is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate safety and efficacy of paltusotine in patients with controlled acromegaly (IGF-I < 1 × ULN) on first-generation SRL injections.